Page 1

Neurocrine® Neurocrine Biosciences Reports Third Quarter 2021 Financial Results November 1 , 2021 INGREZZA® ( valbenazine ) Third Quarter 2021 Net Product Sales of $ 287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO , Nov. 1 , 2021 / PRNewswire / -- Neurocrine Biosciences , Inc. ( Nasdaq : NBIX ) today announced its financial results for the third quarter ended September 30 , 2021 . Neurocrine BIOSCIENCES " Our third quarter results reflect INGREZZA's continued growth . With this momentum and increased investment to expand our commercial footprint , we can better serve patients and our customers , and significantly improve diagnosis and treatment rates for people living with tardive dyskinesia , " said Kevin Gorman , Ph.D. , Chief Executive Officer of Neurocrine Biosciences . " We are prudently investing in our advancing and growing R & D pipeline . With important clinical data read - outs expected over the next two years , we are executing well on our strategy to become a leading neuroscience focused company . " Financial Highlights ( unaudited , in millions , except per share data ) Revenues : Product sales , net Collaboration revenue Total revenues GAAP Research and Development ( R & D ) Non - GAAP R & D GAAP net income ( loss ) GAAP net income ( loss ) per share - diluted Three Months Ended September 30 , 2020 Non - GAAP net income ( loss ) Non - GAAP net income ( loss ) per share - diluted $ $ GAAP Selling , General and Administrative ( SG & A ) $ Non - GAAP SG & A $ $ $ $ $ $ $ 2021 288.8 $ 7.2 296.0 $ 92.7 $ 80.7 $ 154.6 $ 129.5 $ 22.5 $ 0.23 $ 62.6 $ 0.64 $ 254.1 $ 4.4 258.5 $ 69.1 $ 60.3 $ 112.5 $ 94.6 $ ( 57.6 ) $ ( 0.62 ) $ ( 16.9 ) $ ( 0.18 ) $ ( unaudited , in millions ) Total cash , cash equivalents and debt securities available - for - sale Third Quarter INGREZZA Net Product Sales and Commercial Highlights : @ $ Nine Months Ended September 30 , 2020 2021 786.6 $ 34.9 821.5 $ 240.7 $ 204.5 $ 426.8 $ 364.4 $ 96.9 $ 0.99 $ 181.5 $ 1.85 $ 752.8 45.2 798.0 208.3 181.9 326.8 274.2 59.4 0.61 September 30 , December 31 , 2021 2020 1,028.1 1,279.6 $ 163.1 1.66 • Net product sales for the third quarter of 2021 were $ 287 million and $ 285 million on an inventory adjusted basis • Record total prescriptions achieved during the third quarter 2021 reflecting higher customer demand and increased commercial activities • New prescriptions increased throughout the third quarter , reaching their highest levels since March 2020 ● Expanding commercial organization in 2022 to establish dedicated field teams to better meet the needs of healthcare professionals across diverse sites of care and help more patients access effective treatment more quickly Financial Highlights : • Third quarter 2021 GAAP net income and diluted earnings per share were approximately $ 23 million and $ 0.23 , respectively , compared with a net loss and net loss per share of approximately $ 58 million and $ 0.62 , respectively , in the third quarter of 2020 • Third quarter 2021 non - GAAP net income and diluted earnings per share were approximately $ 63 million and $ 0.64 ,